Fluticasone propionate is under clinical development by Eupraxia Pharmaceuticals and currently in Phase II for Eosinophilic Esophagitis. According to GlobalData, Phase II drugs for Eosinophilic Esophagitis have a 75% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Fluticasone propionate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Fluticasone propionate overview

Fluticasone propionate (EP-104) is under development for the treatment of pain associated with osteoarthritis (OA) of the knee. The drug candidate is administered through intraarticular and submucosal route. It is an extended release formulation developed based on sustained release technology, Plexis using large polymer coated particles. It targets the glucocorticoid receptor. It was also under development for diabetic macular edema.

It was also under development for chronic back pain.

Eupraxia Pharmaceuticals overview

Eupraxia Pharmaceuticals is a biotechnology company. It discovers and develops pain management solutions. It is investigating its lead product candidate EP-104IAR for the treatment of osteoarthritis (OA) knee pain. The company is also evaluating EP-201 antibiotic against post-surgical infection; EP-105, an anesthetic solution to treat post-surgical pain; and EP-104IAR program targeting osteoarthritis pain in animals. Eupraxia Pharmaceuticals technology platform encapsulates pharmaceutical micro particles in a polymer shell which helps to extend drug release. It seeks to work in collaboration with global biomedical community to develop existing therapeutics and discover new chemical entities. Eupraxia Pharmaceuticals is headquartered in Victoria, British Columbia, Canada.

For a complete picture of Fluticasone propionate’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.